Jennifer Giltnane
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jennifer Giltnane has a total of 203 co-authors. Here are the top co-authors by number of shared publications:
- Ciara Metcalfe
Discovery Oncology, Genentech, South San Francisco, CA 94080, USA
71 shared publications - Ching-Wei Chang
19PHC and Early Development Oncology Biostatistics, Genentech, Inc., South San Francisco, California
70 shared publications - Heather M. Moore
Translational Medicine – Oncology, Genentech, South San Francisco, USA
70 shared publications - Sarat Chandarlapaty
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA
70 shared publications - Aditya Bardia
University of California Los Angeles, Jonsson Comprehensive Cancer Center, Los Angeles, USA
69 shared publications - Ann Collier
Genentech, Inc., South San Francisco, USA
69 shared publications
Latest Publications
- Open Access
- 1 April 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Loss of luminal lineage drives resistance to next-generation ERα antagonists in pretreated ER+ HER2− locally-advanced or metastatic breast cancer
Next-generation selective estrogen receptor-α (ERα) antagonist/degraders (SERDs) are being developed for ER-positive breast cancer (ER + BC), with intentions of improving outcomes for patients. In recent clinical trials of metastatic ER + BC, next-generation SERDs demonstrated clinical activity, and elacestrant received an approval for advanced ESR1 -mutant disease. However, responses to these drugs were highly heterogeneous: across trials and independent of ESR1 status, 30–50% of patients progressed by their first follow-up scan while other patients sustained benefit for 2 years or more. Here, we interrogate the basis for heterogeneous responses by comparing biopsies from non-responding patients (NR; progression-free survival + BC cell lines exhibit profound shifts in chromatin accessibility, with the transcription factors, FOXA1 and FOXM1, implicated in gene expression of NR-upregulated proliferative pathways.
- 1 April 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessLoss of luminal lineage drives resistance to next-generation ERα antagonists in pretreated ER+ HER2− locally-advanced or metastatic breast cancer
Next-generation selective estrogen receptor-α (ERα) antagonist/degraders (SERDs) are being developed for ER-positive breast cancer (ER + BC), with intentions of improving outcomes for patients. In recent clinical trials of metastatic ER + BC, next-generation SERDs demonstrated clinical activity, and elacestrant received an approval for advanced ESR1 -mutant disease. However, responses to these drugs were highly heterogeneous: across trials and independent of ESR1 status, 30–50% of patients progressed by their first follow-up scan while other patients sustained benefit for 2 years or more. Here, we interrogate the basis for heterogeneous responses by comparing biopsies from non-responding patients (NR; progression-free survival + BC cell lines exhibit profound shifts in chromatin accessibility, with the transcription factors, FOXA1 and FOXM1, implicated in gene expression of NR-upregulated proliferative pathways.
- Open Access
- 3 December 2025
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Non-small cell lung cancer molecular subtypes and vulnerability to immunotherapy treatment combinations
The phase 3 IMpower150 trial in treatment-naïve patients with metastatic non-small-cell lung cancer (NSCLC) demonstrates significantly longer progression-free (PFS) and overall survival (OS) with first-line atezolizumab (anti-PD-L1)-bevacizumab (anti-VEGF)-carboplatin-paclitaxel (ABCP) than with bevacizumab-carboplatin-paclitaxel (BCP). We characterise four molecular NSCLC subtypes identified by unsupervised clustering of transcriptomes of 564 pre-treatment primary tumour samples from IMpower150 using non-negative matrix factorization (NMF1-4). Each subtype has distinct tumour PD-L1 expression levels, epithelial characteristics, immune composition, and treatment outcomes. Both NMF2 (enriched in tumour proliferation signal, macrophages, and monocytes) and NMF4 (enriched in B cells and T cells) have elevated tumour PD-L1 expression. Of these two, only NMF4 demonstrates PFS and OS benefits with ABCP versus either BCP or atezolizumab-carboplatin-paclitaxel (ACP). Patients with NMF1 (enriched in basal and squamous-like cells) have improved outcomes on ABCP compared with ACP or BCP; those with NMF3 (enriched in adenocarcinoma signatures) show similar outcomes among treatments. These insights could help inform individualised first-line treatment for metastatic NSCLC.
- 3 December 2025
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessNon-small cell lung cancer molecular subtypes and vulnerability to immunotherapy treatment combinations
The phase 3 IMpower150 trial in treatment-naïve patients with metastatic non-small-cell lung cancer (NSCLC) demonstrates significantly longer progression-free (PFS) and overall survival (OS) with first-line atezolizumab (anti-PD-L1)-bevacizumab (anti-VEGF)-carboplatin-paclitaxel (ABCP) than with bevacizumab-carboplatin-paclitaxel (BCP). We characterise four molecular NSCLC subtypes identified by unsupervised clustering of transcriptomes of 564 pre-treatment primary tumour samples from IMpower150 using non-negative matrix factorization (NMF1-4). Each subtype has distinct tumour PD-L1 expression levels, epithelial characteristics, immune composition, and treatment outcomes. Both NMF2 (enriched in tumour proliferation signal, macrophages, and monocytes) and NMF4 (enriched in B cells and T cells) have elevated tumour PD-L1 expression. Of these two, only NMF4 demonstrates PFS and OS benefits with ABCP versus either BCP or atezolizumab-carboplatin-paclitaxel (ACP). Patients with NMF1 (enriched in basal and squamous-like cells) have improved outcomes on ABCP compared with ACP or BCP; those with NMF3 (enriched in adenocarcinoma signatures) show similar outcomes among treatments. These insights could help inform individualised first-line treatment for metastatic NSCLC.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. 4 from An Open-label Phase I Study of GDC-0927 in Postmenopausal Women with Locally Advanced or Metastatic Estrogen Receptor–Positive Breast Cancer
Supplementary Fig. S4. ESR1 mutation analysis in ctDNA.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. 4 from An Open-label Phase I Study of GDC-0927 in Postmenopausal Women with Locally Advanced or Metastatic Estrogen Receptor–Positive Breast Cancer
Supplementary Fig. S4. ESR1 mutation analysis in ctDNA.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. 5 from An Open-label Phase I Study of GDC-0927 in Postmenopausal Women with Locally Advanced or Metastatic Estrogen Receptor–Positive Breast Cancer
Supplementary Fig. S5. Kaplan-Meier estimate of progression-free survival for patients with and without ESR1 mutations in baseline ctDNA samples collected from the 1400 mg dose group.ESR1 data was available for 36 of 36 patients dosed at 1400 mg.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. 5 from An Open-label Phase I Study of GDC-0927 in Postmenopausal Women with Locally Advanced or Metastatic Estrogen Receptor–Positive Breast Cancer
Supplementary Fig. S5. Kaplan-Meier estimate of progression-free survival for patients with and without ESR1 mutations in baseline ctDNA samples collected from the 1400 mg dose group.ESR1 data was available for 36 of 36 patients dosed at 1400 mg.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. 3 from An Open-label Phase I Study of GDC-0927 in Postmenopausal Women with Locally Advanced or Metastatic Estrogen Receptor–Positive Breast Cancer
Supplementary Fig. S3. Clinical benefit does not correlate with ctDNA ESR1 mutant allele frequency (MAF) baseline levels or dynamics upon treatment, or with baseline ER and PR protein levels by IHC in tumor tissue.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. 3 from An Open-label Phase I Study of GDC-0927 in Postmenopausal Women with Locally Advanced or Metastatic Estrogen Receptor–Positive Breast Cancer
Supplementary Fig. S3. Clinical benefit does not correlate with ctDNA ESR1 mutant allele frequency (MAF) baseline levels or dynamics upon treatment, or with baseline ER and PR protein levels by IHC in tumor tissue.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. 1 from An Open-label Phase I Study of GDC-0927 in Postmenopausal Women with Locally Advanced or Metastatic Estrogen Receptor–Positive Breast Cancer
Supplementary Fig. S1. Study scheme.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. 1 from An Open-label Phase I Study of GDC-0927 in Postmenopausal Women with Locally Advanced or Metastatic Estrogen Receptor–Positive Breast Cancer
Supplementary Fig. S1. Study scheme.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. 6 from An Open-label Phase I Study of GDC-0927 in Postmenopausal Women with Locally Advanced or Metastatic Estrogen Receptor–Positive Breast Cancer
Supplementary Fig. S6. Detection of short variant gene alterations using the FACT next generation sequencing assay on ctDNA samples from patients dosed at 1400 mg dose (n=23).
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. 6 from An Open-label Phase I Study of GDC-0927 in Postmenopausal Women with Locally Advanced or Metastatic Estrogen Receptor–Positive Breast Cancer
Supplementary Fig. S6. Detection of short variant gene alterations using the FACT next generation sequencing assay on ctDNA samples from patients dosed at 1400 mg dose (n=23).
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data 1 from An Open-label Phase I Study of GDC-0927 in Postmenopausal Women with Locally Advanced or Metastatic Estrogen Receptor–Positive Breast Cancer
Supplementary Tables S1, S2, and S3.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data 1 from An Open-label Phase I Study of GDC-0927 in Postmenopausal Women with Locally Advanced or Metastatic Estrogen Receptor–Positive Breast Cancer
Supplementary Tables S1, S2, and S3.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. 2 from An Open-label Phase I Study of GDC-0927 in Postmenopausal Women with Locally Advanced or Metastatic Estrogen Receptor–Positive Breast Cancer
Supplementary Fig. S2. The PGR z-score for six patients analyzed in Fig. 4.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. 2 from An Open-label Phase I Study of GDC-0927 in Postmenopausal Women with Locally Advanced or Metastatic Estrogen Receptor–Positive Breast Cancer
Supplementary Fig. S2. The PGR z-score for six patients analyzed in Fig. 4.
- Open Access
- 6 January 2025
- Published by Oxford University Press (OUP) in GigaScience
- Vol. 14
SPEX: A modular end-to-end platform for high-plex tissue spatial omics analysis
Recent advancements in transcriptomics and proteomics have opened the possibility for spatially resolved molecular characterization of tissue architecture with the promise of enabling a deeper understanding of tissue biology in either homeostasis or disease. The wealth of data generated by these technologies has recently driven the development of a wide range of computational methods. These methods have the requirement of advanced coding fluency to be applied and integrated across the full spatial omics analysis process, thus presenting a hurdle for widespread adoption by the biology research community. To address this, we introduce SPEX (Spatial Expression Explorer), a web-based analysis platform that employs modular analysis pipeline design, accessible through a user-friendly interface. SPEX’s infrastructure allows for streamlined access to open-source image data management systems, analysis modules, and fully integrated data visualization solutions. Analysis modules include essential steps covering image processing, single-cell analysis, and spatial analysis. We demonstrate SPEX’s ability to facilitate the discovery of biological insights in spatially resolved omics datasets from healthy tissue to tumor samples.
- 6 January 2025
- Published by Oxford University Press (OUP) in GigaScience
- Vol. 14
Open AccessSPEX: A modular end-to-end platform for high-plex tissue spatial omics analysis
Recent advancements in transcriptomics and proteomics have opened the possibility for spatially resolved molecular characterization of tissue architecture with the promise of enabling a deeper understanding of tissue biology in either homeostasis or disease. The wealth of data generated by these technologies has recently driven the development of a wide range of computational methods. These methods have the requirement of advanced coding fluency to be applied and integrated across the full spatial omics analysis process, thus presenting a hurdle for widespread adoption by the biology research community. To address this, we introduce SPEX (Spatial Expression Explorer), a web-based analysis platform that employs modular analysis pipeline design, accessible through a user-friendly interface. SPEX’s infrastructure allows for streamlined access to open-source image data management systems, analysis modules, and fully integrated data visualization solutions. Analysis modules include essential steps covering image processing, single-cell analysis, and spatial analysis. We demonstrate SPEX’s ability to facilitate the discovery of biological insights in spatially resolved omics datasets from healthy tissue to tumor samples.